HTGM · Htg Molecular Diagnostics, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03M | - | $1.25M | $1.49M | $1.18M | - | $2.52M | $2.07M | $1.44M | - |
| Cost of Revenue | $1.15M | - | $670.9K | $1.01M | $855.0K | - | $983.8K | $971.0K | $785.2K | - |
| Gross Profit | ($117.1K) | - | $580.0K | $477.1K | $329.4K | - | $1.54M | $1.10M | $649.9K | - |
| R&D | $1.61M | - | $1.53M | $1.85M | $1.92M | - | $1.53M | $1.28M | $1.37M | - |
| SG&A | $3.28M | - | $3.40M | $4.31M | $4.66M | - | $4.23M | $3.90M | $3.86M | - |
| Total Operating Expenses | $6.05M | - | $5.60M | $7.17M | $7.44M | - | $6.75M | $6.16M | $6.02M | - |
| D&A | $86.1K | - | $100.0K | $200.0K | $185.5K | - | $200.0K | $200.0K | $198.0K | - |
| Operating Income | ($5.01M) | - | ($4.35M) | ($5.68M) | ($6.25M) | - | ($4.23M) | ($4.08M) | ($4.58M) | - |
| Interest Expense | $138.4K | - | $200.5K | $238.5K | $249.3K | - | $266.6K | $260.3K | $270.4K | - |
| Income Tax | $2.2K | - | $1.6K | $4.9K | $386 | - | $1.9K | $16.3K | $2.4K | - |
| Net Income | ($5.05M) | - | ($4.52M) | ($5.89M) | ($6.50M) | - | ($4.49M) | ($2.61M) | ($4.85M) | - |
| EPS - Basic | ($2.28) | - | ($0.41) | ($0.39) | - | - | - | - | - | - |
| EPS - Diluted | ($2.28) | - | ($0.60) | ($0.39) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3.00M | $12.21M | $3.21M | $5.76M | $14.61M | $9.60M | $10.23M | $13.58M | $21.78M | $22.40M |
| Accounts Receivable | $1.13M | $1.42M | $960.4K | $1.26M | $749.2K | $2.09M | $1.90M | $1.42M | $1.25M | $1.59M |
| Inventory | $654.9K | $909.3K | $1.69M | $1.96M | $2.02M | $1.99M | $2.34M | $2.32M | $1.60M | $1.49M |
| Accounts Payable | $1.10M | $1.16M | $709.9K | $1.12M | $1.32M | $1.65M | $1.15M | $1.68M | $1.35M | $1.35M |
| Current Assets | $9.19M | $15.65M | $10.77M | $19.32M | $25.42M | $27.19M | $31.75M | $35.95M | $35.15M | $32.87M |
| Total Assets | $10.87M | $17.78M | $13.61M | $22.21M | $28.46M | $30.46M | $34.51M | $37.32M | $36.63M | $35.20M |
| Current Liabilities | $6.56M | $8.27M | $6.82M | $10.16M | $8.49M | $9.94M | $8.08M | $7.14M | $8.34M | $7.24M |
| Long-term Debt | - | - | $1.30M | $2.02M | $4.05M | $5.18M | $6.31M | $7.44M | $7.05M | $8.57M |
| Total Liabilities | $10.39M | $12.39M | $12.40M | $16.64M | $17.20M | $20.06M | $19.62M | $18.88M | $19.79M | $20.71M |
| Stockholders' Equity | $474.5K | $5.39M | $1.21M | $5.57M | $11.27M | $10.40M | $14.89M | $18.44M | $16.84M | $14.48M |
| Retained Earnings | ($234.98M) | ($229.93M) | ($225.23M) | ($220.72M) | ($214.83M) | ($208.33M) | ($203.14M) | ($198.65M) | ($196.04M) | ($191.19M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.36M) | - | - | - | ($5.94M) | - | - | - | ($4.35M) | - |
| Investing Cash Flow | ($3.54M) | - | - | - | $5.39M | - | - | - | ($2.78M) | - |
| Financing Cash Flow | ($1.31M) | - | - | - | $5.57M | - | - | - | $6.53M | - |
| CapEx | $6.2K | - | - | - | $8.4K | - | - | - | $98.5K | - |
| Free Cash Flow | ($4.37M) | - | - | - | ($5.95M) | - | - | - | ($4.45M) | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | -11.3% | - | 46.4% | 32.0% | 27.8% | - | 61.0% | 53.2% | 45.3% | - |
| Operating margin | -485.5% | - | -347.6% | -380.6% | -528.0% | - | -167.8% | -196.8% | -319.3% | - |
| EBITDA margin | -477.1% | - | -339.6% | -367.2% | -512.3% | - | -159.9% | -187.2% | -305.5% | - |
| Net margin | -489.6% | - | -361.0% | -394.8% | -548.6% | - | -178.2% | -126.1% | -337.8% | - |
| Free cash flow margin | -423.2% | - | - | - | -502.2% | - | - | - | -310.2% | - |
| FCF / Net income | 0.86 | - | - | - | 0.92 | - | - | - | 0.92 | - |
| R&D / Revenue | 156.2% | - | 122.1% | 123.8% | 162.1% | - | 60.9% | 61.8% | 95.6% | - |
| SG&A / Revenue | 318.0% | - | 271.9% | 288.7% | 393.7% | - | 167.9% | 188.2% | 268.9% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -46.5% | - | -33.2% | -26.5% | -22.8% | - | -13.0% | -7.0% | -13.2% | - |
| Return on equity | -1065.3% | - | -373.7% | -105.7% | -57.7% | - | -30.2% | -14.2% | -28.8% | - |
| Return on invested capital | - | - | -136.8% | -59.1% | -32.3% | - | -15.8% | -12.5% | -15.2% | - |
| Liquidity | ||||||||||
| Current ratio | 1.40 | 1.89 | 1.58 | 1.90 | 2.99 | 2.73 | 3.93 | 5.03 | 4.22 | 4.54 |
| Quick ratio | 1.30 | 1.78 | 1.33 | 1.71 | 2.75 | 2.53 | 3.64 | 4.71 | 4.02 | 4.34 |
| Cash ratio | 0.46 | 1.48 | 0.47 | 0.57 | 1.72 | 0.97 | 1.27 | 1.90 | 2.61 | 3.10 |
| Leverage | ||||||||||
| Debt / Equity | - | - | 1.08 | 0.36 | 0.36 | 0.50 | 0.42 | 0.40 | 0.42 | 0.59 |
| Debt / Assets | - | - | 0.10 | 0.09 | 0.14 | 0.17 | 0.18 | 0.20 | 0.19 | 0.24 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -36.2x | - | -21.7x | -23.8x | -25.1x | - | -15.9x | -15.7x | -16.9x | - |
| Equity multiplier | 22.90 | 3.30 | 11.26 | 3.99 | 2.53 | 2.93 | 2.32 | 2.02 | 2.18 | 2.43 |
| Liabilities / Assets | 0.96 | 0.70 | 0.91 | 0.75 | 0.60 | 0.66 | 0.57 | 0.51 | 0.54 | 0.59 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | - | 0.09 | 0.07 | 0.04 | - | 0.07 | 0.06 | 0.04 | - |
| Inventory turnover | 1.76 | - | 0.40 | 0.52 | 0.42 | - | 0.42 | 0.42 | 0.49 | - |
| Days sales outstanding | 400d | - | 280d | 308d | 231d | - | 276d | 250d | 318d | - |
| Days inventory outstanding | 208d | - | 920d | 704d | 863d | - | 868d | 871d | 745d | - |
| Days payable outstanding | 348d | - | 386d | 403d | 562d | - | 425d | 632d | 629d | - |
| Cash conversion cycle | 260d | - | 814d | 609d | 532d | - | 719d | 489d | 434d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -12.8% | - | -50.4% | -28.1% | -17.5% | - | 41.8% | 5.6% | -35.5% | - |
| Revenue CAGR (3y) | -22.6% | - | -38.6% | -32.8% | -28.2% | - | -18.8% | -25.0% | -29.9% | - |
| Revenue CAGR (5y) | -24.3% | - | -19.6% | -3.3% | -2.9% | - | 22.5% | 1.8% | 10.7% | - |
| Gross profit growth (YoY) | - | - | -62.3% | -56.8% | -49.3% | - | 83.8% | 11.6% | -46.3% | - |
| Operating income growth (YoY) | 19.9% | - | -2.8% | -39.1% | -36.5% | - | 18.2% | 18.4% | 15.0% | - |
| Net income growth (YoY) | 22.2% | - | -0.6% | -125.2% | -34.0% | - | 17.0% | 54.2% | 11.2% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 26.5% | - | - | - | -33.6% | - | - | - | -12.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -95.8% | -48.2% | -91.9% | -69.8% | -33.1% | -28.2% | -8.1% | -1.3% | -23.2% | -39.6% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$26.72M totalProduct And Product Related Services$8.91M · 33.3%
Product$5.17M · 19.4%
Consumables Product$3.79M · 14.2%
Product Related Services$3.73M · 14.0%
Sample Processing Product Related Services$3.69M · 13.8%
Instruments Product$1.39M · 5.2%
Custom Assay Design Product Related Services$48.4K · 0.2%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing HTG MOLECULAR DIAGNOSTICS against the 5 most active filers in the same SIC group.